Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cance... (chief executive officer ofMedivation. T...)

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients

Date:4/14/2008

chief executive officer of Medivation. "The analysis of the association between PSA declines and clinical outcomes is ongoing. We look forward to providing additional results from this clinical trial at an upcoming medical conference."

The ongoing Phase 1-2 trial is an open-label U.S. study enrolling prostate cancer patients who have failed standard hormonal therapies. The study is currently planned to enroll patients in 4 dose-expansion cohorts. Of the 21 patients treated at the lowest expanded dose of 60 mg/day evaluated at three months, 43 percent showed a >50 percent decline in PSA levels from baseline. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression.

Medivation expects to complete the study, and report final top-line results, in 2008. If these results are positive, Medivation expects to seek U.S. Food and Drug Administration (FDA) agreement to enter pivotal Phase 3 registration study in castration-resistant prostate cancer.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and castration-resistant (also known as hormone-refractory) prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners a
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Medivation Announces Senior Management Promotions
2. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
3. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
5. Boston Scientific Announces Japanese Approval of Heart Failure Lead
6. Vasogen Announces Implementation of Strategic Restructuring Plan
7. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
8. EXL Announces Appointment of Rembert de Villa as Head of Transformation Services
9. Botaneco Announces Launch of Second Generation Oleosome Product
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Signalife Announces Webcast

Post Your Comments:

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cance...(chief executive officer ofMedivation. T...)